Please enable Javascript
Marginal Zone Lymphoma
The latest news, research, and perspectives in marginal zone lymphoma (MZL).
Advertisement
Favorable Long-Term Data Reported for Axi-cel
Patrick Daly
Marginal Zone Lymphoma
|
November 14, 2023
Axi-cel showed promising efficacy and safety in patients with relapsed or refractory indolent non-Hodgkin lymphomas.
Read More
Two Novel Surrogate Markers for Treatment Effect Validated in Extranodal MZL
Patrick Daly
Marginal Zone Lymphoma
|
November 14, 2023
Two surrogate markers predicted treatment effect on eight-year progression-free survival in patients with extranodal MZL.
Read More
Dr. Nastoupil on Lymphoma Highlights from the SOHO Annual Meeting
Loretta Nastoupil, MD
Meeting News
|
October 26, 2023
Dr. Nastoupil spoke about how the meeting can help clinicians learn how apply knowledge from the latest research.
View More
Loretta Nastoupil, MD, on the Importance of Lymphoma Awareness
Loretta Nastoupil, MD
Video Insights
|
October 15, 2023
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
View More
Data on T-cell Exhaustion Support Earlier Use of T-cell-based Therapies in Splenic MZL
Leah Lawrence
Meeting News
|
September 10, 2023
The composition of T cells in patients with sMZL may affect the efficacy of T-cell-based therapies.
Read More
Ibrutinib on List of First Drugs Selected for Medicare Price Negotiations
Cecilia Brown
Chronic Lymphocytic Leukemia
|
September 1, 2023
Ibrutinib has a monthly sticker price of $17,000 and was taken by 20,000 people who were beneficiaries of Medicare.
Read More
Advertisement
SOHO Ambassador Program Strengthens Global HemOnc Community
Leah Sherwood
Indolent B-Cell Lymphoma
|
October 15, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Read More
FDA Clears IND Application for P-CD19CD20-ALLO1
Leah Sherwood
Aggressive B-Cell Lymphoma
|
July 12, 2023
The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.
Read More
Dose Reduction May Enable Long-term Use of Ibrutinib in B-cell Malignancies
Leah Sherwood
Chronic Lymphocytic Leukemia
|
September 1, 2023
Dose reduction may be a strategy to mitigate the risk of cardiac AEs from recurring or worsening in B-cell malignancies.
Read More
EMA Issues Positive Opinion on Zanubrutinib for Relapsed/Refractory MZL
Leah Sherwood
Marginal Zone Lymphoma
|
November 28, 2022
The European Medicines Agency issued a positive opinion recommending approval of zanubrutinib in adults with MZL.
Read More
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACP
Editor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MD
Associate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MD
Associate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MD
Associate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MD
Associate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MD
Associate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPH
Associate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer